NeuroPace (NASDAQ:NPCE – Get Free Report) and Microbot Medical (NASDAQ:MBOT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.
Volatility and Risk
NeuroPace has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.
Insider and Institutional Ownership
78.8% of NeuroPace shares are owned by institutional investors. Comparatively, 16.3% of Microbot Medical shares are owned by institutional investors. 20.5% of NeuroPace shares are owned by company insiders. Comparatively, 4.7% of Microbot Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| NeuroPace | -21.67% | -108.20% | -18.50% |
| Microbot Medical | N/A | -22.91% | -21.70% |
Analyst Recommendations
This is a summary of current ratings and price targets for NeuroPace and Microbot Medical, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeuroPace | 1 | 1 | 4 | 2 | 2.88 |
| Microbot Medical | 1 | 1 | 2 | 1 | 2.60 |
NeuroPace presently has a consensus target price of $18.67, indicating a potential upside of 18.22%. Microbot Medical has a consensus target price of $7.50, indicating a potential upside of 305.41%. Given Microbot Medical’s higher probable upside, analysts plainly believe Microbot Medical is more favorable than NeuroPace.
Valuation and Earnings
This table compares NeuroPace and Microbot Medical”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeuroPace | $99.53 million | 5.39 | -$21.47 million | ($0.65) | -24.29 |
| Microbot Medical | N/A | N/A | -$13.14 million | ($0.29) | -6.38 |
Microbot Medical has lower revenue, but higher earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.
Summary
NeuroPace beats Microbot Medical on 8 of the 14 factors compared between the two stocks.
About NeuroPace
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
About Microbot Medical
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.
